ReviewFrontiers in aging neuroscience2026
Epigenetics in Alzheimer's disease: from molecular mechanisms to emerging novel biomarkers.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder that represents the leading cause of dementia worldwide, affecting over 50 million people. This global burden is expected to rise dramatically over the coming decades because of global population aging, representing a public health concern. Despite significant advances in understanding AD pathophysiology, early diagnosis remains challenging, emphasizing the urgent need for novel, reliable diagnostic and predictive biomarkers capable of identifying individuals at risk of progression during the preclinical stages of the disease. Growing evidence indicates that epigenetics constitutes a dynamic interface through which aging and environmental exposures influence gene expression and cellular homeostasis, thereby contributing to AD susceptibility and progression. The present review summarizes current knowledge on the epigenetic landscape of AD, from canonical epigenetic mechanisms, including aberrant DNA methylation, histone modifications, and non-coding RNAs (ncRNAs), to the emerging role of mitoepigenetics and RNA methylation in disease-associated molecular mechanisms. Finally, we discuss the potential of epigenetic alterations as promising innovative biomarkers of AD, providing insights into novel avenues for diagnostic and therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.